retatrutide clinical trial results 2024 2025 press release Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 for treatment of type 2 diabetes June 8, 2026: Reckless physicians
Pay in 4 interest-free payments of $5.77 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27


























